PRDM9 and liver cancer: Gene set enrichment analysis (GSEA) of the genes associated with loss of H3K27ac revealed that SETD1A knockdown resulted in loss of SETD1A binding sites signature, histone methyltransferase complex signature, and liver cancer growth–associated, doxorubicin resistance, and MYC target genes, all of which have been reported to be associated with CSCs’ stemness, therapeutic resistance, and tumor progression (33) (Figure 4B).